RESEARCH TRIANGLE PARK, N.C., Nov. 17, 2022 (GLOBE NEWSWIRE) -- G1 Therapeutics, Inc. (Nasdaq: GTHX), a commercial-stage oncology company, today…
BOTHELL, Wash., Nov. 17, 2022 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc. (Nasdaq: COCP) today announced that CC-42344 demonstrated a favorable…
Company’s recent recruitment strategy change has resulted in an unprecedented level of inquiries regarding potential study participationTransplantation of islets into…
-Broad partnership will strengthen Invivyd’s development platform and organizational capabilities towards acceleration of NVD200 clinical program and future engineered antibodies…
COPENHAGEN, Denmark, Nov. 17, 2022 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology…
SAN FRANCISCO, Nov. 16, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced it ranked first on the…
JERUSALEM, Nov. 15, 2022 (GLOBE NEWSWIRE) -- via InvestorWire -- BiondVax Pharmaceuticals Ltd. (Nasdaq: BVXV) (“BiondVax”), a biotechnology company focused…
§ 89% increase in Q3/2022 quarterly revenues as compared with Q3/2021 § Earnings and business update call to be held at 8:30am…
NORCROSS, Ga., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target…
Completed enrollment in the Phase 1 study with novel, broad-spectrum antiviral PB2 candidate CC-42344 for the treatment of pandemic and…